Harald H Sitte
Overview
Explore the profile of Harald H Sitte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
4392
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Belleza O, Saridakis I, Singer N, Westergaard X, Armentia Matheu S, Lemmerer M, et al.
Chem Sci
. 2025 Mar;
PMID: 40070471
Fluorescent labeling techniques have enabled the visualization of various biomolecules, cellular structures, and their associated physiological processes. At the same time, there remains a demand for developing novel fluorescent compounds...
2.
Shah N, Kasture A, Fischer F, Sitte H, Hummel T, Sucic S
Front Mol Neurosci
. 2024 Sep;
17:1466694.
PMID: 39268250
As the first member of the solute carrier 6 (SLC6) protein family, the γ-aminobutyric acid (GABA) transporter 1 (GAT1, ), plays a pivotal role in the uptake of GABA from...
3.
4.
Alberto-Silva A, Hemmer S, Bock H, da Silva L, Scott K, Kastner N, et al.
J Neurochem
. 2024 Jun;
168(9):2022-2042.
PMID: 38898705
3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is re-emerging in clinical settings as a candidate for the treatment of specific neuropsychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive...
5.
Bhatt M, Lazzarin E, Alberto-Silva A, Domingo G, Zerlotti R, Gradisch R, et al.
Cell Mol Life Sci
. 2024 Jun;
81(1):269.
PMID: 38884791
Betaine is an endogenous osmolyte that exhibits therapeutic potential by mitigating various neurological disorders. However, the underlying cellular and molecular mechanisms responsible for its neuroprotective effects remain puzzling.In this study,...
6.
Alberto-Silva A, Hemmer S, Bock H, da Silva L, Scott K, Kastner N, et al.
bioRxiv
. 2024 Apr;
PMID: 38645142
3,4-Methylenedioxymethamphetamine (MDMA, ' ) is re-emerging in clinical settings as a candidate for the treatment of specific psychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a...
7.
Saridakis I, Riomet M, Belleza O, Coussanes G, Singer N, Kastner N, et al.
Angew Chem Int Ed Engl
. 2024 Apr;
63(19):e202318127.
PMID: 38570814
The deployment of small-molecule fluorescent agents plays an ever-growing role in medicine and drug development. Herein, we complement the portfolio of powerful fluorophores, reporting the serendipitous discovery and development of...
8.
Boytsov D, Madej G, Horn G, Blaha N, Kocher T, Sitte H, et al.
Proc Natl Acad Sci U S A
. 2024 Mar;
121(13):e2319686121.
PMID: 38507452
Orphan solute carrier (SLC) represents a group of membrane transporters whose exact functions and substrate specificities are not known. Elucidating the function and regulation of orphan SLC transporters is not...
9.
Puigseslloses P, Nadal-Gratacos N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R, et al.
Mol Psychiatry
. 2024 Mar;
29(8):2346-2358.
PMID: 38486047
Recent studies have sparked renewed interest in the therapeutic potential of psychedelics for treating depression and other mental health conditions. Simultaneously, the novel psychoactive substances (NPS) phenomenon, with a huge...
10.
Gradisch R, Schlogl K, Lazzarin E, Niello M, Maier J, Mayer F, et al.
Nat Commun
. 2024 Jan;
15(1):417.
PMID: 38195746
The presynaptic serotonin transporter (SERT) clears extracellular serotonin following vesicular release to ensure temporal and spatial regulation of serotonergic signalling and neurotransmitter homeostasis. Prescription drugs used to treat neurobehavioral disorders,...